ABSTRACT
Three recent studies revealed synergy between immune-checkpoint inhibitors and the microbiome as a new approach in the treatment of cancer. Incidentally, there has been significant progress in understanding the role of polyunsaturated fatty acids (PUFAs) in modulating cancer and the immune system, as well as in regulating the microbiome. Inflammation seems to be the common denominator among these seemingly unrelated biological entities-immune system, the microbiome, and long-chain polyunsaturated fatty acids (LC-PUFAs). This commentary presents a hypothesis proposing the existence of an optimal level of LC-PUFAs that nurtures the suitable gut microbiota preventing dysbiosis. This synergy between optimal LC-PUFAs and gut microbiota helps the immune system overcome the immunosuppressive tumour microenvironment including enhancing the efficacy of immune checkpoint inhibitors. A model on how LC-PUFAs (such as omega(n)-3 and n-6 fatty acids) forms a synergistic triad with the immune system and the microbiome in regulating inflammation to maintain homeostasis is presented. The principles underlying the hypothesis provide a basis in managing and even preventing cancer and other chronic diseases associated with inflammation.
ABSTRACT
BACKGROUND: Most of the current anti-fungal treatments are chemical-based, fungistatic, have low efficacy in the treatment of tinea and toxicity concerns, while onychomycosis remains recalcitrant to most antifungal therapies. The study aimed to establish the fungicidal, efficacy and safety profile of Calmagen® dermaceutical cream and lotion containing AMYCOT® as a topical treatment in patients with severe to very severe presentations of fungal skin (tinea) and nail infections (onychomycosis). METHODS: A randomized, placebo-controlled, double blind, parallel, single centre study was conducted on 28 subjects with severe to very severe tinea or onychomycosis. All patients were randomized in a ratio of 1:1 for treatment or placebo group. Subjects in the treatment arm received Calmagen® cream or lotion, while subjects in the placebo arm received a similar inert topical preparation. Tinea subjects were treated with cream for four weeks, while onychomycosis subjects were treated with lotion for 12 weeks. Mycological cure, the primary endpoint, was assessed by three parameters: KOH (potassium hydroxide) smear, fungal culture and live spore count. Clinical cure was defined as Investigator Global Assessment (IGA) response of 'cleared' or 'excellent'. RESULTS: All three parameters constituting mycological cure were confirmed in 92.8% (13/14) of subjects in the treatment arm, while all 14 subjects in the placebo arm remained positive for KOH smear. Calmagen® cream and lotion treatment showed a significant improvement in all three parameters: KOH smear, (95% CI (Calmagen): 79.4, 100.0; 95% CI (placebo): 0.0, 0.0; p < 0.0001); fungal culture (95% CI (Calmagen); 100.0, 100.0; 95% CI (Placebo): 17.0, 100.0; p < 0.0019); and live spore count (95% CI (Calmagen): 100.0, 100.0; 95% CI (Placebo): 17.0, 100.0; p < 0.0019). Clinical cure was achieved in all subjects in the treatment arm while none in the placebo arm were clinically cured. No treatment-related adverse effects were observed in either group. CONCLUSIONS: The Calmagen® cream and lotion containing AMYCOT® represent a potentially safe and efficacious natural alternative in the treatment of Tinea and onychomycosis. TRIAL REGISTRATION: This trial has been registered with the clinical trial registry-India (CTRI; registration number: CTRI/2012/03/002522 ).
Subject(s)
Anti-Infective Agents/administration & dosage , Onychomycosis/drug therapy , Tinea/drug therapy , Administration, Topical , Adult , Double-Blind Method , Female , Humans , India , Male , Middle Aged , Treatment Outcome , Young AdultABSTRACT
PURPOSE: A phytochemical- and mineral-rich filtered sugarcane molasses concentrate (FMC), when added to carbohydrate-containing foods as a functional ingredient, lowers postprandial blood glucose and insulin responses. We hypothesised that this beneficial effect would also occur if FMC was administered as an oral supplement taken before a meal. METHODS: This study measured the postprandial glucose and insulin responses elicited by different doses of FMC administered immediately prior to a standard breakfast to healthy subjects. Each subject was given three or five breakfast meals once, on different days. The composition of the meals was identical, except for the addition of either placebo syrup (test meal 1) or increasing doses of FMC (test meals 2-5). RESULTS: The plasma glucose concentration curves were similar for the five test meals. Plasma insulin curves were lowered in a dose-dependent manner. Stratifying subjects based on age, BMI and insulin resistance showed greater effects of low doses of FMC on lowering insulin responses in those subjects with potentially greater insulin resistance. When insulin response is standardised to amount of carbohydrate in the meal/dose combination, the reduction in response is linear and inversely proportional to the FMC dose. CONCLUSIONS: FMC shows promise as an agent that can reduce insulin responses and lessen the load on the pancreatic beta cells.
Subject(s)
Insulin/blood , Molasses/analysis , Postprandial Period , Saccharum/chemistry , Adolescent , Adult , Blood Glucose/metabolism , Body Mass Index , Breakfast , Cross-Over Studies , Dietary Carbohydrates/administration & dosage , Dietary Carbohydrates/analysis , Dietary Fats/administration & dosage , Dietary Fats/analysis , Dietary Fiber/administration & dosage , Dietary Fiber/analysis , Dietary Proteins/administration & dosage , Dietary Proteins/analysis , Dose-Response Relationship, Drug , Energy Intake , Female , Humans , Insulin Resistance , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Male , Micronutrients/administration & dosage , Micronutrients/analysis , Phytochemicals/administration & dosage , Phytochemicals/analysis , Single-Blind Method , Young AdultABSTRACT
The development of effective diagnostic tools will be essential in the continuing fight to reduce schistosome infection; however, the diagnostic tests available to date are generally laborious and difficult to implement in current parasite control strategies. We generated a series of single-chain antibody Fv domain (scFv) phage display libraries from the portal lymph node of field exposed water buffaloes, Bubalus bubalis, 11-12 days post challenge with Schistosoma japonicum cercariae. The selected scFv-phages showed clear enrichment towards adult schistosomes and excretory-secretory (ES) proteins by immunofluorescence, ELISA and western blot analysis. The enriched libraries were used to probe a schistosome specific protein microarray resulting in the recognition of a number of proteins, five of which were specific to schistosomes, with RNA expression predominantly in the adult life-stage based on interrogation of schistosome expressed sequence tags (EST). As the libraries were enriched by panning against ES products, these antigens may be excreted or secreted into the host vasculature and hence may make good targets for a diagnostic assay. Further selection of the scFv library against infected mouse sera identified five soluble scFv clones that could selectively recognise soluble whole adult preparations (SWAP) relative to an irrelevant protein control (ovalbumin). Furthermore, two of the identified scFv clones also selectively recognised SWAP proteins when spiked into naïve mouse sera. These host B-cell derived scFvs that specifically bind to schistosome protein preparations will be valuable reagents for further development of a cost effective point-of-care diagnostic test.
Subject(s)
Antibodies, Helminth/metabolism , Antigens, Helminth/analysis , Buffaloes/parasitology , Peptide Library , Schistosoma japonicum/immunology , Serologic Tests/methods , Single-Chain Antibodies/metabolism , Animals , Antibodies, Helminth/genetics , Antigens, Helminth/immunology , Blotting, Western , Buffaloes/immunology , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Mice , Protein Array Analysis , Single-Chain Antibodies/geneticsABSTRACT
Antibodies isolated from the local draining inguinal lymph node of field exposed-water buffaloes following challenge with Schistosoma japonicum cercariae showed high reactivity towards S. japonicum antigen preparations and bound specifically to formaldehyde-fixed S. japonicum schistosomules. Using this specific local immune response we produced a series of single-chain antibody Fv domain libraries from the same lymph nodes. Removal of phage that cross reacted with epitopes on adult parasites yielded a single-chain antibody Fv domain-phage library that specifically bound to whole formaldehyde-fixed and live S. japonicum schistosomules. DNA sequencing indicated clear enrichment of the single-chain antibody Fv domain library for buffalo B-cell complementarity determining regions post-selection for schistosomule binding. This study also revealed that long heavy chain complementarity determining regions appear to be an important factor when selecting for antibody binding fragments against schistosomule proteins. The selected single-chain antibody Fv domain-phage were used to probe a schistosome-specific protein microarray, which resulted in the recognition of many proteins expressed across all schistosome life-cycle stages. Following absorption to adult worms, the single-chain antibody Fv domain-phage library showed significantly reduced binding to most proteins, whilst two proteins (NCBI GenBank accession numbers AY915878 and AY815196) showed increased binding. We have thus developed a unique set of host derived single-chain antibody Fv domains comprising buffalo B-cell variable regions that specifically bind to early S. japonicum life-stages.
Subject(s)
Antibodies, Helminth/immunology , Buffaloes , Schistosoma japonicum/growth & development , Schistosoma japonicum/immunology , Schistosomiasis japonica/immunology , Schistosomiasis japonica/veterinary , Single-Chain Antibodies/immunology , Animals , Antibodies, Helminth/isolation & purification , Antigens, Helminth/immunology , Larva/growth & development , Larva/immunology , Lymph Nodes/immunology , Protein Array Analysis , Single-Chain Antibodies/isolation & purificationABSTRACT
An aqueous filtered molasses concentrate (FMC) sourced from sugar cane was used as a functional ingredient in a range of carbohydrate-containing foods to reduce glycaemic response. When compared to untreated controls, postprandial glucose responses in the test products were reduced 5-20%, assessed by accredited glycaemic index (GI) testing. The reduction in glucose response in the test foods was dose-dependent and directly proportional to the ratio of FMC added to the amount of available carbohydrate in the test products. The insulin response to the foods was also reduced with FMC addition as compared to untreated controls. Inclusion of FMC in test foods did not replace any formulation ingredients; it was incorporated as an additional ingredient to existing formulations. Filtered molasses concentrate, made by a proprietary and patented process, contains many naturally occurring compounds. Some of the identified compounds are known to influence carbohydrate metabolism, and include phenolic compounds, minerals and organic acids. FMC, sourced from a by-product of sugar cane processing, shows potential as a natural functional ingredient capable of modifying carbohydrate metabolism and contributing to GI reduction of processed foods and beverages.
Subject(s)
Blood Glucose/metabolism , Diet , Dietary Carbohydrates/metabolism , Glycemic Index , Insulin/metabolism , Molasses , Saccharum , Adolescent , Adult , Functional Food , Humans , Postprandial Period , Saccharum/chemistry , Young AdultABSTRACT
The monoclonal IgM antibody PAT-SM6 derived from human tumours induces apoptosis in tumour cells and is considered a potential anti-cancer agent. A primary target for PAT-SM6 is the unfolded protein response regulator GRP78, over-expressed externally on the cell surface of tumour cells. Small angle X-ray scattering (SAXS) studies of human GRP78 showed a two-domain dumbbell-shaped monomer, while SAXS analysis of PAT-SM6 revealed a saucer-shaped structure accommodating five-fold symmetry, consistent with previous studies of related proteins. Sedimentation velocity analysis of GRP78 and PAT-SM6 mixtures indicated weak complex formation characterized by dissociation constants in the high micromolar concentration range. In contrast, enzyme-linked immunosorbant assays (ELISAs) showed strong and specific interactions between PAT-SM6 and immobilized GRP78. The apparent binding constant estimated from a PAT-SM6 saturation curve correlated strongly with the concentration of GRP78 used to coat the microtiter tray. Experiments using polyclonal antiGRP78 IgG antibodies or a monoclonal IgG derivative of PAT-SM6 did not show a similar dependence. Competition experiments with soluble GRP78 indicated more effective inhibition of PAT-SM6 binding at low GRP78 coating concentrations. These observations suggest an avidity-based binding mechanism that depends on the multi-point attachment of PAT-SM6 to GRP78 clustered on the surface of the tray. Analysis of ELISA data at high GRP78 coating concentrations yielded an apparent dissociation constant of approximately 4 nM. We propose that the biological action of PAT-SM6 in tumour cell apoptosis may depend on the multivalent nature of PAT-SM6 and the high avidity of its interaction with multiple GRP78 molecules clustered on the tumour cell surface.
Subject(s)
Antibodies, Monoclonal/immunology , Antibody Specificity , Antineoplastic Agents/immunology , Heat-Shock Proteins/immunology , Immunoglobulin M/immunology , Endoplasmic Reticulum Chaperone BiP , Enzyme-Linked Immunosorbent Assay , Humans , Immobilized Proteins/immunology , SolutionsABSTRACT
Vaccines are effective in preventing disease by stimulating the immune system and sustaining an immune response towards eradication of pathogens and diseased cells. However, designing successful vaccines is not always straightforward. For a vaccine to be successful, antigen-presenting cells (APC) need to be stimulated, primarily by adjuvants, towards a sustained immune response through integration of the innate and adaptive (humoral and cellular) immune systems. Furthermore, there is an immediate need for safe and effective adjuvants. There has been significant progress in understanding the mechanisms on how vaccines work and the role of adjuvants, dendritic cells, and the toll-like receptor (TLR) pathway. Currently, different adjuvants are actively explored but the potential of the immunoglobulin M (IgM) as a vaccine adjuvant has been overlooked. This article hypothesizes how the IgM molecule could function as a vaccine adjuvant by acting as a "soluble" toll-like receptor (TLR) through the formation of an immune complex with antigen (Ag) and other components of the innate immune system. The complex should lead to sustained humoral and/or cell-mediated immune responses. Hypothetically, it is also possible that the Ag-IgM complex recruits other components of complement or other factors that can activate other members of the adaptive immune system. As it is now possible to produce commercial-scale quantities of monoclonal human IgM antibodies, understanding the role of the IgM in linking the innate and adaptive immune systems may lead to practical therapeutic applications.
Subject(s)
Adjuvants, Immunologic , Immunoglobulin M/immunology , Vaccines/immunology , Animals , Antibody Formation , Humans , Immunity, Cellular , Toll-Like Receptors/metabolismABSTRACT
Given that proteomic analysis of complex protein mixtures may be restricted by the presence of highly abundant proteins, sample preparation to remove abundant proteins is essential for the analysis of low abundance proteins. Chickens are effective producers of antibodies (IgY) against mammalian proteins, able to produce large quantities of antibodies that can be recovered by simple non-intrusive extraction of egg yolk. The extraction procedure described uses a modification of the water dilution method (WD) to deplete lipids and lipoproteins followed by sequential precipitation with 31% ammonium sulphate and 12% poly ethylene glycol (PEG) producing IgY antibodies with greater than 95% purity and no loss in immunoreactivity. In the present study, various cocktails of the 12 most abundant human plasma proteins were used as immunogens to produce IgY antibodies. The anti-cocktail IgY antibodies were effectively used to sequentially and selectively immunodeplete abundant proteins from plasma. Also, affinity depletion (e.g., Affi-Gel Blue) was combined with immunodepletion to sequentially deplete abundant proteins from both plasma and urine. The current approach described allows the end user to mix and match sets of IgY cocktails to deplete tailored sets of targeted proteins dependent on their end use application.
Subject(s)
Immunoglobulins/immunology , Proteins/isolation & purification , Animals , Chickens , Chromatography, Affinity , Chromatography, High Pressure Liquid , Electrophoresis, Polyacrylamide Gel , Humans , Mass Spectrometry , Proteins/immunologyABSTRACT
Natural IgM antibodies play an important role in the body's defense mechanisms against transformed cells in the human body and are currently being exploited both in prognoses of malignant lesions and in the therapy of cancer patients. However, despite growing interest and clinical promise, thus far the IgM class of antibodies has failed to gain widespread commercial interest as these are considered to be difficult to produce recombinantly. IgMs are polymeric and have a relatively large mass. In addition, IgM molecules are heavily glycosylated and, when produced in non-human cell lines, they may contain non-human glycan structures which may be potentially immunogenic. Clearly, production systems capable of expressing human recombinant IgM antibodies are needed. We have successfully used PER.C6 cells-a human cell line-to generate three separate human recombinant monoclonal IgMs in suspension cultures in protein-free medium. All three of the IgMs were constructed with joining (J) chain and were expressed in the pentameric form. One of the IgMs was also expressed as a hexamer without J chain. Clones with cell specific productivities greater than 20 pg/cell/day were generated, which led to yields of 0.5 g/L to 2g/L in fed-batch production. All the IgMs expressed were biologically active as shown in binding and cytotoxicity assays. These studies demonstrate the potential of PER.C6 cells for the production of high levels of functional recombinant IgM and other polymeric molecules, using a straightforward and rapid stable cell line generation method.
Subject(s)
Antibodies, Monoclonal/biosynthesis , Immunoglobulin M/biosynthesis , Recombinant Proteins/biosynthesis , Adenocarcinoma , Antibodies, Monoclonal/genetics , Bioreactors , Biotechnology/methods , Carcinoma , Cell Culture Techniques , Cell Line , Cell Line, Tumor/immunology , Culture Media, Serum-Free , Gene Expression Regulation , Humans , Immunoglobulin M/genetics , Lung Neoplasms , Pancreatic Neoplasms , Recombinant Proteins/geneticsABSTRACT
This commentary evaluates the newly proposed concept of crypteins - peptides with embedded cryptic activity - as a source of peptide drugs. Although several crypteins are undergoing advanced clinical trials, and one cryptein, adrenocorticotropic hormone (ACTH), is already widely used as a therapeutic, crypteins remain an underappreciated class of biopharmaceuticals. The systematic exploitation of crypteins provides a novel source of peptide drugs, and may also provide templates for developing peptidomimetic compounds. In addition, crypteins appear to offer several advantages over synthetic protein libraries and other protein scaffolds.
Subject(s)
Peptide Fragments/chemistry , Peptide Fragments/pharmacology , Animals , Humans , Peptide Library , PharmacologyABSTRACT
There is increasing evidence that proteolytic cleavage gives rise to 'hidden' peptides with bioactivities that are often unpredicted and totally distinct to the parent protein. So far, the liberation of these cryptic peptides, or crypteins, has been shown to be prevalent in proteins associated with endocrine signalling, the extracellular matrix, the complement cascade and milk. A broad spectrum of proteases has been implicated in the generation of natural crypteins that appear to play a role in modulating diverse biological processes, such as angiogenesis, immune function and cell growth. The proteolytic liberation of crypteins with novel activities represents an important mechanism for increasing diversity of protein function and potentially offers new opportunities for protein-based therapeutics.
Subject(s)
Peptides/metabolism , Proteome , Angiogenesis Inhibitors/pharmacology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Collagen/chemistry , Collagen/metabolism , Drug Design , Humans , Milk Proteins/chemistry , Milk Proteins/metabolism , Peptide Hydrolases/metabolism , Peptides/chemistry , Pro-Opiomelanocortin/chemistry , Pro-Opiomelanocortin/metabolism , Protein Processing, Post-TranslationalSubject(s)
Drug Design , Drug Industry , Animals , Antibodies, Monoclonal , Australia , Biotechnology , Humans , Peptide LibraryABSTRACT
Biopharmaceuticals, mainly protein-based therapeutics, are rapidly being developed for several disease indications. However, most biopharmaceuticals are 'me-too' drugs or are being developed against the same handful of targets. Thus, the potential of biopharmaceuticals is not being fully exploited. The bottleneck is still the lack of validated targets and the means of implementing the appropriate target validation technology. Functional proteomic screens provide a rapid route to accelerate the discovery and development of the next generation of biopharmaceuticals.
Subject(s)
Drug Evaluation, Preclinical/methods , Proteins/pharmacology , Proteomics/methods , Antibodies/immunology , DNA/genetics , DNA/metabolism , HumansABSTRACT
Apoptotic evasion is a hallmark of cancer and its resistance to chemotherapeutic drugs. Identification of cellular proteins that mediate apoptotic programs is a critical step toward the development of therapeutics aimed at overcoming apoptosis resistance. We developed an innovative high-throughput screen to identify proteins that modulate Fas ligand-mediated apoptosis using fluorophore-assisted light inactivation (HTS-FALIpop). The FALI protein knockdown strategy was coupled to a caspase activity assay with the ability to detect both proapoptotic and antiapoptotic surface molecules expressed by HT-1080 human fibrosarcoma cells. FALI of the Fas receptor (Fas/CD95) using a fluorescein-conjugated anti-Fas antibody abrogated Fas ligand-mediated caspase activation. Ninety-six single-chain variable fragment antibodies (scFv), selected for binding to the surface of HT-1080 cells, were screened by HTS-FALIpop. Three of the scFvs caused decreases in caspase induction after FALI of their protein targets. One of the targets of these positive scFvs was identified as CD44 and was validated by performing FALI using a CD44-specific monoclonal antibody, which resulted in similar protection from Fas apoptosis. CD44-targeted FALI was antiapoptotic in multiple human cancer cell lines, including both Fas signaling type I and II cells, and was also protective against other ligands of the tumor necrosis factor death receptor family. FALI of CD44 inhibited formation and activation of the death-inducing signaling complex, suggesting that CD44 regulates Fas at the cell surface. This mechanism of death receptor regulation represents a novel means of apoptosis modulation that could be exploited by pharmacologic agents.
Subject(s)
Apoptosis , Hyaluronan Receptors/metabolism , Immunoglobulin Fragments/immunology , Proteomics , Receptors, Tumor Necrosis Factor/metabolism , fas Receptor/metabolism , Animals , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/pathology , Caspases/metabolism , Death Domain Receptor Signaling Adaptor Proteins , Enzyme Activation , Fibrosarcoma/metabolism , Fibrosarcoma/pathology , Humans , Hyaluronan Receptors/genetics , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Lymphoma, T-Cell/metabolism , Lymphoma, T-Cell/pathology , Mammary Neoplasms, Experimental/metabolism , Mammary Neoplasms, Experimental/pathology , Mass Spectrometry , Mice , Tumor Cells, Cultured , fas Receptor/geneticsABSTRACT
BACKGROUND: Invasion is an important early step of cancer metastasis that is not well understood. Developing therapeutics to limit metastasis requires the identification and validation of candidate proteins necessary for invasion and migration. METHODS: We developed a functional proteomic screen to identify mediators of tumor cell invasion. This screen couples Fluorophore Assisted Light Inactivation (FALI) to a scFv antibody library to systematically inactivate surface proteins expressed by human fibrosarcoma cells followed by a high-throughput assessment of transwell invasion. RESULTS: Using this screen, we have identified CD155 (the poliovirus receptor) as a mediator of tumor cell invasion through its role in migration. Knockdown of CD155 by FALI or by RNAi resulted in a significant decrease in transwell migration of HT1080 fibrosarcoma cells towards a serum chemoattractant. CD155 was found to be highly expressed in multiple cancer cell lines and primary tumors including glioblastoma (GBM). Knockdown of CD155 also decreased migration of U87MG GBM cells. CD155 is recruited to the leading edge of migrating cells where it colocalizes with actin and alphav-integrin, known mediators of motility and adhesion. Knockdown of CD155 also altered cellular morphology, resulting in cells that were larger and more elongated than controls when plated on a Matrigel substrate. CONCLUSION: These results implicate a role for CD155 in mediating tumor cell invasion and migration and suggest that CD155 may contribute to tumorigenesis.
Subject(s)
Cell Movement , Membrane Proteins/analysis , Neoplasm Invasiveness , Neoplasm Proteins/analysis , Receptors, Virus/analysis , Cell Line, Tumor , Fibrosarcoma/metabolism , Fibrosarcoma/pathology , Fibrosarcoma/secondary , Glioblastoma/metabolism , Glioblastoma/pathology , Glioblastoma/secondary , Humans , Immunoprecipitation/methods , Membrane Proteins/physiology , Neoplasm Proteins/physiology , Proteomics/methods , Receptors, Virus/physiologyABSTRACT
Tumour cell invasiveness is crucial for cancer metastasis and is not yet understood. Here we describe two functional screens for proteins required for the invasion of fibrosarcoma cells that identified the molecular chaperone heat shock protein 90 (hsp90). The hsp90 alpha isoform, but not hsp90 beta, is expressed extracellularly where it interacts with the matrix metalloproteinase 2 (MMP2). Inhibition of extracellular hsp90 alpha decreases both MMP2 activity and invasiveness. This role for extracellular hsp90 alpha in MMP2 activation indicates that cell-impermeant anti-hsp90 drugs might decrease invasiveness without the concerns inherent in inhibiting intracellular hsp90.
Subject(s)
Cell Membrane/metabolism , Extracellular Matrix/metabolism , Fibrosarcoma/physiopathology , HSP90 Heat-Shock Proteins/metabolism , Matrix Metalloproteinase 2/metabolism , Neoplasm Invasiveness/physiopathology , Basement Membrane/metabolism , Binding Sites/physiology , Cell Line, Tumor , Enzyme Inhibitors/pharmacology , Fibrosarcoma/metabolism , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Humans , Protein Binding/physiology , Protein Interaction Mapping , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Protein Structure, Tertiary/physiology , ProteomicsABSTRACT
The targets of more than 95% of clinically approved drugs are proteins. Thus, the plethora of targets derived from genomics and proteomics efforts must be validated at the protein level. However, most of the preferred target validation technologies are gene- or transcript-based. Protein-based or proteinetic approaches, which are more relevant to determine target druggability, are now emerging.:
ABSTRACT
Technological advances in miniaturization have found a niche in biology and signal the beginning of a new revolution. Most of the attention and advances have been made with DNA chips yet a lot of progress is being made in the use of other biomolecules and cells. A variety of reviews have covered only different aspects and technologies but leading to the shared terminology of "biochips." This review provides a basic introduction and an in-depth survey of the different technologies and applications involving the use of non-DNA molecules such as proteins and cells. The review focuses on microarrays and microfluidics, but also describes some cellular systems (studies involving patterning and sensor chips) and nanotechnology. The principles of each technology including parameters involved in biochip design and operation are outlined. A discussion of the different biological and biomedical applications illustrates the significance of biochips in biotechnology.